Infinity Pharma stock gains 24% on survival analysis data for a phase 2 trial, Q2 results

Retrieved on: 2022-08-11 03:09:48

Tags for this article:

Clinical medicine

Drugs

Transitional cell carcinoma

Infi

Transitional epithelium

Revenue

Getty Images

Infinity Pharmaceuticals

Click the tags to see associated articles and topics

Infinity Pharma stock gains 24% on survival analysis data for a phase 2 trial, Q2 results. View article details on HISWAI: https://seekingalpha.com/news/3870784-infinity-pharma-stock-gains-24-on-survival-analysis-data-for-a-phase-2-trial-q2-results

Excerpt

Shares of micro-cap clinical-stage biotech Infinity Pharmaceuticals (INFI) jumped 24.3% to $0.92 in Wednesday mid-day trading, after it announced ...

Article found on: seekingalpha.com

View Original Article